State Street
RLMD icon

State Street’s Relmada Therapeutics RLMD Stock Holding History

State Street’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.48M Buy
357,040
+36,220
+11% +$171K ﹤0.01% 3234
2025
Q4 		$1.55M Buy
320,820
+219,000
+215% +$734K ﹤0.01% 3415
2025
Q3 		$205K Sell
101,820
-4,915
-5% -$4.71K ﹤0.01% 3908
2025
Q2 		$64.1K Hold
106,735
– – ﹤0.01% 4054
2025
Q1 		$28.8K Hold
106,735
– – ﹤0.01% 4163
2024
Q4 		$55.5K Buy
106,735
+7,500
+8% +$18.3K ﹤0.01% 4094
2024
Q3 		$322K Sell
99,235
-6,644
-6% -$21.5K ﹤0.01% 3693
2024
Q2 		$318K Sell
105,879
-5,250
-5% -$19K ﹤0.01% 3678
2024
Q1 		$517K Sell
111,129
-4,100
-4% -$19.8K ﹤0.01% 3639
2023
Q4 		$477K Hold
115,229
– – ﹤0.01% 3651
2023
Q3 		$346K Sell
115,229
-14,200
-11% -$42.2K ﹤0.01% 3763
2023
Q2 		$318K Sell
129,429
-421,667
-77% -$1.17M ﹤0.01% 3846
2023
Q1 		$1.25M Buy
551,096
+55,363
+11% +$191K ﹤0.01% 3464
2022
Q4 		$1.73M Sell
495,733
-94,401
-16% -$829K ﹤0.01% 3420
2022
Q3 		$21.8M Sell
590,134
-11,051
-2% -$306K ﹤0.01% 2153
2022
Q2 		$11.4M Buy
601,185
+155,621
+35% +$3.39M ﹤0.01% 2641
2022
Q1 		$12M Buy
445,564
+122,163
+38% +$2.53M ﹤0.01% 2719
2021
Q4 		$7.29M Sell
323,401
-2,470
-0.8% -$54.9K ﹤0.01% 3068
2021
Q3 		$8.54M Buy
325,871
+15,707
+5% +$420K ﹤0.01% 2974
2021
Q2 		$9.93M Buy
310,164
+19,579
+7% +$680K ﹤0.01% 2925
2021
Q1 		$10.2M Sell
290,585
-13,874
-5% -$485K ﹤0.01% 2732
2020
Q4 		$9.76M Buy
304,459
+2,138
+0.7% +$73.5K ﹤0.01% 2642
2020
Q3 		$11.4M Buy
302,321
+17,550
+6% +$678K ﹤0.01% 2372
2020
Q2 		$12.7M Buy
284,771
+276,371
+3,290% +$11.7M ﹤0.01% 2286
2020
Q1 		$287K Buy
+8,400
New +$339K ﹤0.01% 3532

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street's RLMD Position: Q1 2026 in Review

State Street increased its Relmada Therapeutics (RLMD) stake by 11% in Q1 2026, buying an estimated $171K and bringing the position to 357,040 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3234.

State Street first reported a position in RLMD in Q1 2020 and has held it in 25 quarters since. The position peaked at $21.8M in Q3 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • State Street held 357,040 shares of Relmada Therapeutics worth $2.48M as of Q1 2026.
  • State Street bought 36,220 Relmada Therapeutics shares in Q1 2026, an estimated $171K.
  • Relmada Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3234 holding.
  • State Street first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • State Street's Relmada Therapeutics position peaked at $21.8M in Q3 2022.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.